Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Asia Manufacturing PMI Rebounds as Exports and Tech Demand Drive Growth into 2026 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Japanese Business Leaders Urge Government Action as Weak Yen Strains Economy 
U.S. Stocks Slip as Gold Rebounds Ahead of Year-End, Markets Eye 2026 Outlook 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
U.S. Dollar Slides Toward Biggest Annual Loss Since 2017 as 2026 Risks Loom 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
China Manufacturing PMI Rebounds in December, Offering Boost to Economic Growth Outlook 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
USDA $12 Billion Farm Aid Program Draws Mixed Reactions from Row Crop Farmers 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Samsung Biologics signed a new deal with GSK, formerly GlaxoSmithKline. This will be their second manufacturing deal, and this time the agreement value is $296.1 million.
The amount is said to be almost 30% of the full-year revenue of Samsung last year, which was KRW1.5 trillion or around $1 billion, and the contract with GSK is in effect until the end of 2030. Samsung Biologics is currently the top Contract Manufacturing Organization in the world in terms of capacity, and its latest deal with the said British pharmaceutical industry company is for the supply of biopharma products.
Samsung Biologics and GSK plc confirmed their second collaborative contract late last week. As per The Korea Economic Daily, the biotech unit of the Samsung Group did not disclose the details of the exact products it will make for GSK under their contract.
One of their earlier deals was signed in May 2020, and it was a contract worth $231 million. It was also for the supply of biopharma products for eight years since the contract was made official. To be more specific, this was for the production and delivery of GSK’s Benlysta (belimumab) drug, which is used for the treatment of the autoimmune disease - lupus nephritis.
GSK and Samsung Biologics expanded their deal and signed another contract in August 2020, which was worth $368.1 million. It was a CMO agreement to produce sotrovimab, a SARS-CoV-2 monoclonal antibody that targets the COVID-19 virus.
In any case, the new deal is a remarkable expansion of the business relationship between Samsung Biologics and GSK. They already partnered in several projects, and now larger contracts are coming up
Meanwhile, Fierce Pharma reported that the new agreement comes as Samsung Biologics launches its “Super Plant,” which is also its fourth manufacturing facility. It sits in the company’s huge complex in Incheon, South Korea. It has invested more than $2 billion in the construction of this massive plant as part of its ambitious plan to become a major global player in the contract development and manufacturing organization scene.
